To sum up, GH001 has shown us pretty robust efficacy, a strong safety profile, and durable antidepressant effects. Going into ...
The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate ...
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
In addition to the IND approval, Cartography Bio also announced that CBI-1214 has been granted Fast Track designation by the FDA. This status is designed to facilitate the development and expedited ...
FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON, Aug. 25, 2025 ...
Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital will participate in Capsida Biotherapeutics' multicenter clinical ...
The FDA issued an RFI seeking venture capital input on a new contract model to connect portfolio companies directly with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback